Posts Tagged 'sglt2 inhibitors'

Trouble for Diabetes Drug Makers?

invokana and farxiga mdls to move forwardKnown as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.

Unfortunately, this relatively new class of drugs has already allegedly caused enough harm to warrant FDA action ...

continue reading...

Invokana May Actually Increase Risk of Diabetes Amputations

invokana may increase risk of diabetes-related amputationsThe effects of diabetes on a patient’s body are numerous and wide-ranging. In some cases, the inability to regulate insulin production is the only impact and is resolved in a seemingly simple way. Injection, diet, or an insulin pump that be used to take over sugar regulation for the diabetic. In other cases, however, the patient’s battle is an arduous one and strict compliance with physicians’ instructions is the only ...

continue reading...

Lopez McHugh Files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury

PHILADELPHIA (December 2015) – The national trial lawyers of Lopez McHugh have filed a lawsuit against Johnson & Johnson and its subsidiary, Janssen, alleging that its diabetes medication, Invokana®, causes patients to develop diabetic ketoacidosis.

The lawsuit (Case No. 15-12-00653) was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis but failed to warn doctors.

Diabetic ketoacidosis is a condition where the body produces ketones, ...

continue reading...

Invokana Class-Action Lawsuit Filed in Canada

The diabetes drug Invokana has become the focus of a national class-action lawsuit in Canada, CBC Nova Scotia reports. According to a statement filed in the Ontario Supreme Court of Justice, the lead plaintiff alleges that Janssen Pharmaceuticals’ new sodium-glucose cotransporter-2 (SGLT2) inhibitor was responsible for her kidney failure.

SGLT2 inhibitors, a new line of type 2 diabetes medications, work by directing excess blood sugars to be eliminated through urine. But not long after they reached the ...

continue reading...

Case Report Highlights Diabetic Ketoacidosis Risk with SGLT2 Inhibitors

Another case report links sodium-glucose co-transporter 2 (SGLT2) inhibitors like Invokana to diabetic ketoacidosis, a severe and potentially fatal condition wherein the body produces too many blood acids. The article, published in the journal Practical Diabetes, presents the case of a 58-year-old woman who suffered severe diabetic ketoacidosis after her twice-daily insulin regimen was replaced by dapagliflozin.

SGLT2 inhibitors, the new class of type 2 diabetes medication introduce in 2013, were first linked to ketoacidosis ...

continue reading...

First Study on SGLT2 Inhibitor Use in Type 1 Diabetics Shows Increased Diabetic Ketoacidosis

sglt2 inhibitor results fall shortAccording to a Medscape article, the results of the first-ever Phase 2 study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in type 1 diabetes patients have been reported—and they may not be as reassuring as many had hoped. The data were presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting by Robert R. Henry, MD, chief of the Division of Endocrinology and Metabolism at the University of ...

continue reading...
Page 1 of 3 123